Philadelphia
WuXi PharmaTech will begin construction in spring of 2015 on a 145,000-sf cGMP facility in Philadelphia. The project is expected to be operational by mid-2016 and will support the manufacture of cell therapy products for personalized medicine, including chimeric antigen receptor T cells.
Source
